GS-US-563-5926: Oral Weekly Islatravir/ Lenacapavir Regimen in People with HIV-1 Who are Virologically Suppressed on Standard of Care

A Phase 3 Randomized, Active-Controlled, Open-Label Study to Evaluate a Switch to an Oral Weekly Islatravir/ Lenacapavir Regimen in People with HIV-1 Who are Virologically Suppressed on Standard of Care